Russell Investments Group Ltd. Sells 40,380 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Russell Investments Group Ltd. lessened its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 10.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 344,923 shares of the medical equipment provider's stock after selling 40,380 shares during the quarter. Russell Investments Group Ltd. owned 0.10% of Intuitive Surgical worth $116,383,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of ISRG. Portside Wealth Group LLC lifted its stake in shares of Intuitive Surgical by 8.2% in the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider's stock worth $275,000 after acquiring an additional 62 shares in the last quarter. Sequoia Financial Advisors LLC increased its holdings in Intuitive Surgical by 58.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider's stock valued at $2,805,000 after buying an additional 3,054 shares during the last quarter. Kades & Cheifetz LLC bought a new stake in Intuitive Surgical in the fourth quarter valued at about $230,000. Blair William & Co. IL increased its holdings in Intuitive Surgical by 3.1% in the third quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider's stock valued at $110,302,000 after buying an additional 11,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Intuitive Surgical by 21.2% in the third quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider's stock valued at $216,140,000 after buying an additional 129,194 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Intuitive Surgical Stock Up 0.6 %

NASDAQ ISRG traded up $2.21 on Friday, reaching $375.33. 927,845 shares of the stock traded hands, compared to its average volume of 1,564,565. The firm's fifty day simple moving average is $386.19 and its 200 day simple moving average is $346.74. The company has a market cap of $133.13 billion, a price-to-earnings ratio of 67.75, a P/E/G ratio of 4.85 and a beta of 1.36. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company's revenue was up 11.5% compared to the same quarter last year. During the same period last year, the company posted $1.00 EPS. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, VP Marshall Mohr sold 108,790 shares of the firm's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the sale, the vice president now directly owns 26,877 shares of the company's stock, valued at approximately $10,349,795.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, SVP Mark Brosius sold 196 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares in the company, valued at $736,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Marshall Mohr sold 108,790 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares of the company's stock, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. Insiders sold a total of 249,418 shares of company stock valued at $96,300,959 in the last three months. 0.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on ISRG shares. Robert W. Baird lowered their price objective on Intuitive Surgical from $440.00 to $436.00 and set an "outperform" rating for the company in a report on Friday, April 19th. StockNews.com lowered Intuitive Surgical from a "buy" rating to a "hold" rating in a report on Thursday, February 29th. Raymond James upped their target price on Intuitive Surgical from $372.00 to $435.00 and gave the company an "outperform" rating in a report on Thursday, January 25th. Wells Fargo & Company upped their target price on Intuitive Surgical from $363.00 to $416.00 and gave the company an "overweight" rating in a report on Friday, January 19th. Finally, Piper Sandler upped their target price on Intuitive Surgical from $425.00 to $435.00 and gave the company an "overweight" rating in a report on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and a consensus target price of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.